Dabrafenib combined with trametinib: efficacy and safety of dual-targeted therapy

Dabrafenib (Dabrafenib) combined with Trametinib/Megenin (Trametinib) is a classic BRAF and MEK dual-targeted treatment regimen, mainly used for patients with BRAF Patients with advanced solid tumors with V600E or V600K mutations have achieved remarkable therapeutic effects, especially in melanoma, thyroid cancer, and non-small cell lung cancer. This combination regimen is based on the precise regulation of theRAS-RAF-MEK-ERK signaling pathway and aims to overcome the possible resistance problems caused by a single BRAF inhibitor, thereby extending progression-free survival (PFS) and overall survival (OS), improving objective response rate (ORR) and reducing treatment-related toxicity.

Dabrafenib is an oral BRAF inhibitor that specifically acts on the mutated BRAF V600E kinase, inhibiting its activation of downstream MEK, thereby preventing the abnormal proliferation of cancer cells. However, monotherapy with BRAF inhibitors often leads to drug resistance due to feedback activation of the MEK-ERK pathway. Therefore, adding the MEK inhibitor trametinib can further block the signaling pathway, form a more complete inhibition, reduce the occurrence of drug resistance from the mechanism level, and improve the efficacy. Trametinib itself is a highly selective oral MEK1/2 inhibitor. Its combination with dabrafenib can achieve dual blockade of the upstream and downstream signaling pathways, which is a typical application of multi-target strategies in the era of precision medicine.

In the treatment of melanoma, Two key phase III clinical studies of COMBI-d and COMBI-v showed that the combination of dabrafenib + trametinib significantly improved the median progression-free survival (11.0 months vs. 8.8 months) and median overall survival (25.1 months vs. 18.7 months) compared with BRAF inhibitor alone. The objective response rate exceeded 65%, and has long-term response potential. This result promotes this combination to become the first-line standard regimen for the treatment of BRAF V600 mutated advanced melanoma. In addition, in NSCLC patients carrying BRAF mutations, this combination regimen also demonstrated a response rate of nearly 65% u200bu200band durable disease control capabilities, and is particularly suitable for patients who have not received BRAF-targeted therapy in the past. In addition, some patients with BRAF mutation-positive thyroid cancer and biliary tract cancer also showed certain responses, expanding the potential indications of this regimen.

Regarding safety, although dabrafenib combined with trametinib slightly increases some toxicity compared with single drug, the overall tolerability is still considered good, and the side effects can be greatly alleviated through dose adjustment. Common adverse reactions include fever (one of the most common side effects), fatigue, rash, gastrointestinal reactions (such as nausea, vomiting, diarrhea), redness and swelling of extremities, elevated liver enzymes, etc. In particular, febrile reactions require close monitoring and symptomatic treatment in actual use. In severe cases, the drug may need to be temporarily discontinued or the regimen adjusted. In addition, MEK inhibitors may be associated with adverse reactions related to cardiac function and vision. Therefore, it is recommended to regularly check electrocardiogram, left ventricular ejection fraction (LVEF) and ophthalmological evaluation during treatment to ensure the safety of medication.

From the perspective of long-term efficacy, although some patients will develop drug resistance within 6-12 months of treatment, the combination regimen delays the emergence of drug resistance compared with single targeted therapy. In the future, research based on the combination of immunotherapy and targeted drugs is also actively promoted. For example, combination with PD-1 inhibitors has shown enhanced anti-tumor activity and immunomodulatory effects in multiple trials, providing more possibilities for patients with advanced tumors.

Reference materials:https://go.drugbank.com/drugs/DB08911